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ABSTRACT 
Oesophageal squamous cell carcinoma (OSCC) is a highly malignant tumour that has a poor 
prognosis and shows marked regional variation in its incidence, implicating environmental 
factors. South Africa is one of several countries that has areas of high incidence. The exact 
aetiopathogenesis of OSCC is not well understood. Current environmental risk factors include 
alcohol, tobacco, human papillomavirus (HPV) infection and nutritional factors including; low 
intake of Vitamins A, C and riboflavin, lack of fruit and vegetables, ingestion of fungal 
contaminated foods and consumption of extremely hot beverages. This study was a retrospective 
immunohistochemical study done on paraffin embedded tissues. The histopathology, grading 
and staging of all resected squamous cell carcinomas over a twenty one year period from 1982 to 
2002, were reviewed. Sixty eight patients were identified; all had an oesophagectomy for OSCC 
at Groote Schuur Hospital, a tertiary referral centre. Clinical details regarding gender, race, age, 
smoking or alcohol usage and survival data were collected. Survival data was updated to 23 
June 2003. Two paraffin blocks representing OSCC and normal mucosa for each patient were 
retrieved from the archives in the Division of Anatomical Pathology. In addition 16 cases of 
reflux oesophagitis were included for comparison. Initial immunohistochemical staining for 
HPV (Dako- clone KlH8) was undertaken but the negative results necessitated a shift in the 
focus of this study to that of cell cycle regulatory proteins. The tissues were evaluated for p53 
(Dako - clone D0-7), p2l (Novocastro - clone 4Dl0), cyclin DI (Dako - clone DCS-6) and 
cyclin E (Novocastro - clone 13A3). Expression was interpreted as positive if 10% or more of 
the tumour cell population stained. Expression was also stratified into three levels (1, 2 and 3) 
depending on the percentage positive staining. Normal mucosa did not stain for any of the cell 
cycle regulators. OSCC stained as follows: 61.8% for p53, 27.9% for p21, 22.1 % for cyclin E 
and 44.1% for cyclin Dl. Reflux oesophagitis stained as follows: 31.2% for cyclin DI, 12.5% 
for p21 and 0% for both p53 and cyclin E. Subsequent statistical analysis failed to reveal any 
prognostic significance to the expression of cell cycle regulators, nor could expression or level of 
expression be associated with stage, grade, age, gender or alcohol use. There was however a 
significant relationship between cyclin DI and smoking. In addition expression of p53 
discriminated between malignant and reactive oesophageal lesions. Advancing age proved to be 
associated with an increased risk of mortality. Lastly, histopathological staging proved to be the 




Squamous cell carcinoma of the oesophagus (OSCC) is a major health problem in the world and 
particularly in certain geographic areas of South Africa where the incidence is amongst the 
highest in the world. In the majority of South African cases the patients present late with 
progressive dysphagia, advanced carcinomas and are not amenable to surgical or oncological 
therapy thus the outcome is generally poor. As a result the incidence and mortality rates of 
oesophageal cancers in South Africa are almost equal. My experience as a Medical Officer in 
the Eastern Cape province of South Africa revealed it to be a tragic and formidable disease. 
1.2 EPIDEMIOLOGY OF OESOPHAGEAL SQUAMOUS CELL 
CARCINOMA 
In industrialised countries, the age standardized incidence does not exceed 5/100000 in males 
and l /I 00000 in females. However there are occasional striking geographical exceptions, such as 
Normandy in France, where the incidence may be as high as 30/100000 in males (1 ). 
Oesophageal cancer is the eighth most frequent cancer in the world (2). 
Regions of very high incidence have been identified in Iran, Central China, South Africa and 
Southern Brazil ( Graph 1.1 ). Studies in the United States of America have shown that the 
incidence differs amongst race groups where it has been found to be 2 to 3 times more frequent 
in Blacks as compared to Asians, Whites or Native Americans (3 ). According to the WHO 2000 
report, the incidence of oesophageal cancer in South Africa males is 11, 9/100000 ( 4 ). 
Graph 1.1: Bar graph of worldwide annual incidence of OSCC in males/100000. Adapted from 
the WHO (!ARC) publication Tumours of the digestive system (4) 
• soum AFRICA 






0 20 40 60 
WORLDWIDE INCIDENCE PER 100,000 MALES 
However, several studies done in the former 'Transkei' region of South Africa, in an area that 
is 
now known as the Eastern Cape, show an incidence of OSCC to be in excess of 100/10000
0 
males and more than 25/100000 in females (5-8). Interestingly, this rate of malignancy does no
t 
appear confined to the rural areas with studies from urban indigenous African population
s 
showing similarly high age standardised incidences (9-11 ). 
1.3 AETIOPATHOGENESIS 
A better understanding of the aetiological agents and molecular mechanisms involved in th
e 
development of OSCC may offer opportunities to reduce exposure to environmental risk factor
s, 
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allow early diagnosis and predict response to therapy. Epidemiologic studies have identified 
multiple risk factors. Smoking, alcohol consumption, diets poor in fresh fruit and vegetables, 
consumption of foods contaminated with Fusarium verticillioides, aflatoxin and HPV infection 
are risk factors associated with the development of this disease in Africa (2). 
1.3.1 Alcohol and tobacco: 
It has been estimated that these two factors together account for approximately 80% of 
oesophageal cancer in males from France, USA, Japan and Latin American countries (Graph 1.2) 
(12-14 ). The risk has been shown to increase relative to the amount and type of alcohol 
consumed; spirits confer greater risk than wine or beer ( 15). A study from the UK demonstrated 
variations in the rates of oesophageal carcinoma which parallel total alcohol consumption (16). 
Chronic alcohol use interferes with the absorption and metabolism of folate, B-carotene and 
vitamin A thus possibly compounding carcinogenic potential (17-20). In addition home brewed 
alcoholic beverages in South Africa have been shown to contain carcinogenic contaminants such 
as mycotoxins, methans and tannins (21, 22). Studies from Japan done in people with high 
alcohol consumption show a polymorphism in the aldehyde dehydrogenase 2 gene. This is 
significantly associated with several upper digestive tract cancers including OSCC and suggests 
that acetaldehyde, a carcinogenic metabolite of alcohol that has recently been shown to cause 
DNA damage, may play a significant role (23). 
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Graph 1.2: Age-standardised incidence rates of OSCC. Adapted from the WHO (IARC)-2000, 
Tumours of the digestive tract. The proportion of OSCC attributed to alcohol and tobacco is also 
supplied in percentages next to the relevant geographic area (4). 
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There is a significantly higher incidence of OSCC among smokers or those who chew tobacco 
when compared to those who abstain from tobacco use (24). Autopsy material from American 
men comparing oesophageal mucosa in smokers and non-smokers found atypical nuclei present 
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in approximately 6% of non-smokers while almost 80% of smokers had nuclear atypia (25 ). It 
has been suggested that in the South African high risk population, tobacco use plays a more 
important aetiological role than alcohol (26). Practices such as swallowing the pipe dottle from 
the pipe stem and scraping and chewing the residue in these pipes are cultural practices that 
prevail in many of the rural communities of South Africa. Similar situations exist in high 
incidence areas of North-eastern Iran where eating residues from opium pipes is widespread; 
these tobacco and opium pyrolysis products are mutagenic in the Ames test (27). 
Epidemiological studies in France determined chewing tobacco and hand rolled cigarettes to be 
major risk factors for oesophageal carcinoma. The former increasing the risk in the upper 
oesophagus and the latter the lower part (28). 
13.2 Diet: 
Dietary surveys in Northern Iran found clear regional variations with diet, areas where diets 
consisted mainly of homemade bread and tea had a high incidence. These populations had low 
vitamin A, riboflavin and vitamin C intake (29). Similar deficiencies exist in high incidence 
rural areas in China and South Africa. In addition contamination of stored food by fungal 
species such as Fusarium, Geotrichum and Aspergillus occurs in rural areas. These fungi induce 
the formation of nitrosamines (30), which are potent oesophageal carcinogens in the laboratory 
rat (31 ). Fusarium species have been shown to produce the mycotoxins fumonisin Bl and B2 
that are responsible for hepatic and renal cancer in rats. These mycotoxins are currently regarded 
as possible carcinogens in OSCC and hepatocellular carcinomas in humans. Deficiencies of 
elements such as zinc have also been associated with OSCC (32). Evidence that fruit and 
vegetables protect against OSCC is gradually accumulating (33 ). Another risk factor related to 
diet is the drinking of burning hot beverages such as Mate tea in South America which result in 
thermal injury and associated chronic oesophagitis and dysplasia (34-36). 
5 
1.3.3 Infectious agents: 
Numerous investigators, prompted by the relevance of human papillomavirus (HPV) 
to 
squamous cell carcinoma at sites such as the cervix and anus, have searched for HPV in t
he 
oesophagus. Prevalence rates vary greatly from 0-65% in different studies (37-39). The
se 
variable results can be attributed to two factors: the different techniques us
ed 
(immunohistochemistry, m situ hybridisation, polymerase chain reaction and southern b
lot 
technique - Table 1.3) and the source population. Notably within the different populatio
ns 
studied there is a tendency for a higher incidence of oesophageal carcinoma to be associated w
ith 
a higher prevalence of oesophageal HPV infection ( 40, 41 ). However the certainty with whic
h 
HPV is implicated as a carcinogenic factor in OSCC is questioned in the literature. Wheth
er 
HPV is an incidental finding or relevant to OSCC remains controversial. The relative
ly 
consistent observation is that the HPV detection rate is absent (42-45) or significantly lower (4
0, 
46) in areas of a moderate or low incidence of OSCC. While in the extremely high inciden
ce 
areas HPV's detection rate is in the region of 50% or higher using techniques sensitive 
to 
detecting integrated HPV (47-49). It has been proposed that HPV replication stops before 
or 
during malignant transformation (50) and that HPV acts synergistically with other initiati
ng 
events, such as environmental factors, for carcinogenesis (51 ). A study using oesophageal c
ell 
lines demonstrated that carcinogenesis of oesophageal epithelial cells, induced by HPV, is a 
multistage process, which goes through the initial, immortal, premalignant and maligna
nt 
transformation stages (52). The current evidence would support a role for HPV, particularly 
in 
high incidence areas of OSCC. Graph 1.3 (below) demonstrates the commonly used methods f
or 
detecting HPV in OSCC, the range of results and the average positive result. There a
re 
important differences between the individual studies, such as the population studied, antibo
dy 
clone or specific primers used that the table does not account for. What it attempts to highlight
 is 
the difference in sensitivity and average positivity between differing detection methods. 
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Graph 1.3: Toe prevalence of HPV in OSCC by: (1) IHC- immunohistochemical (37, 38, 53), 
(2) ISH- in-situ hybridisation (48, 54-66), (3)PCR- polymerase chain reaction (40-47, 49, 54, 67-
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The possibility that other viruses (herpes simplex virus, cytomegalovirus, and Epstein-Barr 
virus) are potential aetiological factors has also been raised (77). 
1.3.4 Genetic factors: 
Individuals with autosomal dominantly inherited keratosis plantaris and palmaris (Tylosis) are at 
high risk for OSCC; the authors suggest affected people have a 90 to 95% chance of developing 
OSCC by 65 years of age (89). Ashworth and colleagues studied two Tylotic families and 
compared them to inflammatory controls and found a significant increase in single cell 
keratinisation in the Tylotic group (90). Abnormalities in the tylosis oesophageal carcinoma 
(TOC) gene have been found in both Tylosis associated and sporadic OSCCs (91). Studies from 
high incidence areas of Northern Iran, showed that 47% of OSCC patients gave a positive family 
history of OSCC, compared to only 2% from low incidence areas of Iran (92). The tylosis gene 
has not been studied in South African patients with OSCC. 
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1.3.5 Other factors: 
OSCC occurs with increased frequency in patients with achalasia (93 ), oesophageal diverticulae 
(94, 95), Plummer-Vinson syndrome (96), coeliac disease (97), duplication cysts of the 
oesophagus (98, 99), therapeutic radiation involving the oesophagus (IOO)) and stricture 
formation following lye ( crude sodium hydroxide with sodium carbonate) ingestion (IO 1-103 ). 
All of these diseases have the common link of being associated with chronic oesophagi tis. 
1.4 CLINICAL ASPECTS: 
The clinical symptoms and signs are mainly due to narrowing of the oesophageal lumen by 
tumour growth and include dysphagia, weight loss, epigastric or retrostemal discomfort and 
regurgitation. Certain populations of central, eastern, and southern Africa display very high 
incidence rates of OSCC, presenting a serious health burden to the continent. Most patients are 
diagnosed at a late stage because of the asymptomatic development of the disease, with 
associated poor prognosis. Squamous cell carcinoma is the most prevalent oesophageal 
malignancy worldwide and tends to occur with a higher incidence in developing countries. 
OSCC is found predominately in the lower and middle third of the oesophagus. Approximately 
10% are located in the upper third of the oesophagus. 
1.4.1 Special investigations: 
Oesophagography: Using radiological contrast media (usually barium) lesions may be detected 
within the lumen of the oesophagus. The sensitivity of this method is questionable and given 
that patients require a biopsy for a histological diagnosis of malignancy, it is becoming less 
popular. 
Endoscopy: This procedure allows the investigator to identify and sample the lesion 
simultaneously. Malignant lesions may be divided into three types endoscopically: flat, 
ulcerated or polypoid. In addition chromoendoscopy, using either toluidine blue or Lugol's 
iodine spray, may be of value particularly in identifying early, small lesions. Toluidine blue, a 
metachromatic stain that binds to DNA and RNA, helps identify areas richer in nuclei than the 
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surrounding normal oesophageal mucosa (104). Lugol's iodine reacts with glycogen in the 
normal oesophageal mucosa giving a purplish colour while dysplastic, malignant, reactive 
lesions and heterotopic tissue do not stain ( I 05). 
Endoscopic ultrasonography: Oesophageal carcinoma is generally viewed as a localised or 
diffuse wall thickening with a predominately echo poor or inhomogeneous pattern. This 
technique is mainly used to evaluate depth of invasion and paraoesophageal lymph node 
involvement ( I 06) 
Computed tomography and magnetic resonance imaging: These investigations are useful when 
advanced lesions are suspected giving information on local and systemic spread. In particular, 
lymph node enlargement may be accurately assessed ( I 07) 
Cytology: Endoscopic brush cytology is slowly gammg acceptance as a useful screening 
procedure for premalignant and malignant lesions particularly in areas of high incidence. This 
technique is dependant on the technology employed to obtain and prepare the sample, and the 
skill and experience of the examining cytopathologist or technologist. 
Histology: Biopsy and histopathological examination 1s a relatively simple procedure and 
remains the gold standard for the diagnosis of oesophageal malignancy. 
1.5 PATHOLOGY: 
Oesophageal carcinoma occurs as two main subtypes, squamous cell carcinoma (more prevalent 
in developing countries) and adenocarcinoma (more common in developed countries and usually 
associated with reflux oesophagitis complicated by Barrett's disease). These account for more 
than 90% of oesophageal malignancies. Other histological types of carcinoma seen in the 
oesophagus include adenosquamous, mucoepidermoid, adenoid cystic, small cell neuroendocrine 
and undifferentiated. On rare occasions other malignant lesions such as melanomas, 
leiomyosarcomas, carcinoid tumours, Kaposi sarcoma, gastrointestinal stromal tumours, 
rhabdomyosarcomas and lymphomas may present primarily in the oesophagus. OSCC develops 
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as the result of a sequence of histopathological changes that typically involves oesophagitis, 
atrophy, mild to severe dysplasia, carcinoma in situ and finally, invasive cancer. 
1.5.1 Macroscopic: 
The typical appearance of OSCC is that of an exophytic, ulcerated and/or infiltrating lesion that 
often results in a stricture. However, when the malignancy undermines the surrounding normal 
mucosa it may appear as a smooth annular stenosis. Submucosal extension is often present and 
may result in satellite nodules. Multifocal primary carcinomas are not uncommon but it is 
important to exclude submucosal or intramural spread before making this diagnosis. 
1.5.2 Microscopic: 
OSCC is defined as the penetration of neoplastic squamous cells through the basement 
membrane and extension into the surrounding lamina propria or deeper tissues of the 
oesophagus. Along with vertical tumour growth a horizontal proliferation is usually present that 
undermines the adjacent normal mucosa at the tumour periphery. The carcinoma often shows 
early invasion into intramural lymphatic channels and veins. In advanced lesions the carcinoma 
invades the muscular layers, the adventitia and may extend beyond by invading adjacent organs 
or tissues. The formation of oesophago-tracheal or oesophago-bronchial fistulae is not 
uncommon. The degree of stromal desmoplasia and inflammatory response are variable. Thus 
OSCC is variable in its appearance and attempts to categorise these appearances histologically 
led to the development of a grading system. 
1.5.3 Grading: 
OSCC is currently graded according to the traditional parameters of degree of differentiation, 
anisonucleosis and mitotic activity. These parameters are subjective and as no objective 
acceptable criteria exist the grading of OSCC results in considerable inter-observer variation 
(108-112). 
Well differentiated: These tumours show both cytological and histological features that are 
similar to the normal oesophageal squamous epithelium. Well differentiated tumours are 
composed predominantly of large differentiated, keratinocyte-like squamous cells with a low 
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proportion of basal-type cells. The malignant cells are often arranged in nests with central 
keratinisation and intercellular bridges between the cells. These intercellular bridges are an 
integral part of normal squamous epithelium and are referred to as 'prickle cells'. Interestingly, 
keratinisation has been interpreted as a sign of differentiation even though the normal 
oesophageal mucosa is non-keratinising. 
Moderately differentiated: This is the most common type of OSCC and lies between well and 
poorly differentiated tumours in its appearance. 
Poorly differentiated: These tumours consist predominantly of basal-type cells that have a high 
mitotic rate, they usually lack squamous differentiation/maturation but when present, it is 
minimal and focal (4). The malignant cells often are show basaloid, sarcomatoid/spindled or 
discohesive morphology. Immunohistochemical and ultrastructural studies are often required to 
help confirm the diagnosis. 
1.5.4 Staging: 
The TNM (tumour, node and metastasis) system established by the International Union Against 
Cancer is the most widely used system. The usefulness of this system in treatment planning and 
prognostication has been validated ( 113-116). 
TNM staging of oesophageal carcinoma: 
T-primary tumour 
TX- primary tumour cannot be assessed. 
TO- No evidence of a primary tumour. 
Tis- Carcinoma in-situ. 
pTl- tumour invades lamina propria or submucosa. 
pT2- tumour invades muscularis propria. 
pT3- tumour invades the adventitia. 
pT4- tumour invades adjacent structures. 
N-Regional lymph nodes 
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NX- Regional lymph nodes cannot be assessed. 
pNO- no regional lymph node metastases. 
pN I- regional lymph node metastasis present. 
M-Distant metastasis 
MX- distant metastasis cannot be assessed. 
MO- no distant metastasis. 
MI- distant metastasis are present, where MI a = metastasis in celiac lymph nodes. M 1 b = other 
distant metastasis. 
Staging is therefore as follows: 
Stage O = Tis NO MO 
Stage I = Tl NO MO 
Stage IIA = T2 NO MO 
orT3 NO MO 
Stage IIB = Tl NI MO 
orT2N1 MO 
Stage Ill = T3 N 1 MO 
orT4 anyN MO 
Stage IVA= any T any N Mia 
Stage IVB =any T any N Mlb. 
1.6 MOLECULAR PATHOLOGY: 
Genetic changes associated with the development of OSCC include mutation of the p53 gene, 
disruption of cell-cycle control in G 1 by several mechanisms (inactivation of pl 6MTS1, 
amp! i fication of cyclin DI, alterations of retinoblastoma ), activation of oncogenes (HST- I, HST-
2, EGFR, c-MYC), and inactivation of several tumor suppressor genes. Amplification of cyclin 
DI is frequently detected in cancers that retain expression of retinoblastoma (Rb) protein 
consistent with the notion that these two factors cooperate within the same signalling cascade 
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(117). Inactivation of cyclin dependant kinase 2A occurs in advanced OSCC and is thought to be 
due either to homozygous deletion or de novo methylation. Loss of heterozygosity on 
chromosome l 7q25 has been linked with tylosis (nonepidermolytic palmoplantar keratoderma), a 
rare autosomal dominant syndrome associated with high predisposition to OSCC. The TOC 
gene has been mapped to chromosome l 7q25 a tumour suppressor gene which shows 
abnormalities in both tylosis associated/hereditary and sporadic OSCC (91). Chronic 
oesophagitis is a frequent histological finding in OSCC specimens and in some instances, 
patches of positive cells in areas of oesophagitis at the margins of tumours were found to contain 
a mutation in the p53 gene. This observation is consistent with field cancerization in the 
oesophagus and suggests that oesophagitis may represent an interesting target for early detection 
of OSCC as well as for intervention strategies ( 118). 
Other possible important genetic events include inactivation of the fragile histidine triad (FHJT) 
gene, an assumed tumour suppressor gene at 3p 14 (117). 'Frequent loss of heterozygosity occurs 
at 3p21.3 in OSCC' and analysis of clones 'led to the discovery of a novel gene called DLCJ 
(deleted in lung and oesophageal cancer-I)' (119). Reverse transcriptase-PCR experiments 
indicate that approximately 33% of primary OSCC lack DLCJ transcripts entirely or contain 
increased levels of non-functional DLCl mRNA. There is also evidence that loss of 
heterozygosity at 5p 15 occurs in a large portion of OSCC suggesting a possible tumour 
suppressor function ( 120). 
How these genetic events interrelate and result in carcinoma, with phenotypic variations, remains 
speculative. 
1. 7 PROGNOSTIC FACTORS: 
The overall prognosis of OSCC is dismal with an average 10% 5-year survival rate. One met-
analytical review revealed that 'of I 00 patients with OSCC, 39 will be surgically resectable, 26 
will leave hospital and only 4 will be alive after 5 years' (121). Local recurrence is common 
following surgical resection ( 122). Currently the best chance at cure is achieved by early 
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focused on surgical outcome while studies on other forms of therapy have shown a survival 
advantage to those receiving combined chemoradiotherapy when compared to those treated with 
radiotherapy alone (l 23). However chemotherapy alone has been shown to result in tumour 
regression (124, 125). 
l) Staging: This is the single most important prognostic factor currently known. Several 
studies have shown that the depth of invasion and presence of nodal metastases are both 
independent predictors of survival (l 13, 115, 116). The majority of studies have used the 
TNM classification to determine the prognostic significance but the current TNM system 
does not differentiate between tumours confined to the mucosa and those involving the 
submucosa. This has been shown to be of considerable prognostic significance (126, l 27). 
2) Differentiation: Poor standardisation of grading criteria has led to equivocal results, while 
some studies have shown grade to convey prognostic significance (128, 129), the majority 
did not find any significance to grading ( 108-112). 
3) Vascular and lymphatic invasion: Several studies have shown these are poor prognostic 
factors (113, 130). 
4) Lymphocytic response: The presence of an intense lymphocytic response has been 
associated with a better prognosis ( 108, 131 ). 
5) Ploidy: Flow cytometry or image analysis studies have found that aneuploidy is present in 
55-95% of OSCCs and that patients with diploid tumours usually have a longer survival. 
However prognostic significance independent of tumour stage has only been shown in 
some studies (132-134). 
6) Molecular factors: In addition to cell cycle regulatory proteins (discussed below), a number 
of molecular factors have shown prognostic significance. 
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Epidermal growth factor receptor has been shown as a potential prognostic factor with 
over expression conferring a worse prognosis. The few studies done in this regard have 
shown conflicting results ( 135, 136). 
Redox defence system components (137, 138) and matrix proteinases (139-141) have been 
reported as conveying prognostic value. 
Caspase-3 expression correlated with a significantly favorable prognosis m primary 
resected OSCC in multivariate analysis ( 129). 
None of the above molecular factors are used in routine clinical practice. 
1.8 CELL CYCLE REGULATORY PROTEINS: 
1.8.1 P53: 
P53 is a critical controller of normal growth and homeostasis of cells and tissues (142). The p53 
gene is located on the short arm of chromosome 17 and is responsible for the production of the 
p53 protein. This is a phosphoprotein with a molecular weight of 53 kilodaltons. It is a tumour 
suppressor gene whose inappropriate function may lead to disordered growth and malignancy. 
Normal or 'wild type' p53 protein acts as the 'guardian of the genome' by inhibiting mitosis in 
cells with damaged DNA. The p53 protein acts on other genes to arrest the cell cycle until the 
damaged DNA is repaired or to cause apoptosis. Normal p53 is upregulated in cells with 
damaged DNA, such as that caused by UV light, ionising radiation, chemotherapeutic agents or 
following hypoxia. P53 inhibits progression into the S phase of the cell cycle by inhibition of 
cyclin dependant kinases (CDK's) due to upregulation of p2 I CIPI protein, and proliferating cell 
nuclear antigen (PCNA). The GADD45 (growth arrest DNA damaged) protein is also up-
regulated which in tum also binds to PCNA. The cell is thereby arrested in the GI phase. If 
DNA repair fails then wild type p53 can trigger apoptosis, although apoptosis may also be 
triggered by other means. The loss of the normal function of p53 usually occurs by a two-step 
process with a mutation of one allele and a deletion or inactivation of the second allele. Chen 
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and colleagues (143) used generated cell lines and showed that the cellular level of p53 can 
dictate the response of the cell such that lower levels of p53 result in arrest, whereas higher 
levels result in apoptosis; nevertheless they found DNA damage can heighten the apoptotic 
response to p53 without altering the protein level of p53 in cells. They also demonstrated that 
arrest and apoptosis are two genetically separable functions of p53 because a transcriptionally 
incompetent p53 can induce apoptosis but not arrest, whereas induction of p21 WAFJ, which is a 
major transcriptional target of p53, can induce arrest but not apoptosis. A full apoptotic response 
to p53 requires both its amino and carboxyl terminus, suggesting there is synergism between 
transcription-dependent and -independent functions of p53 in apoptosis. P53 is mutated in more 
than 50% of human cancers (142). 
Normal cells are in a balance between growth promotion, cellular differentiation and growth 
restraint. In cancers, mutations of p53 result in progression of cells through the cell cycle. 
Patients with the rare Li-Fraumeni syndrome inherit germline mutations of p53 on one allele. 
The subsequent loss of the only wild type p53 allele leads to multiple tumours (adrenal cortex, 
brain, breast, sarcomas and various types of leukaemia ( 144-146). However, several common 
malignancies that frequently have p53 mutations, such as colorectal carcinoma do not occur with 
increased frequency in Li-Fraumeni syndrome. This is probably due to the fact that p53 loss is a 
relatively late event in colorectal carcinogenesis, after Ki-ras activation and loss of 'deleted in 
colorectal carcinoma' (DCC) gene (14 7). 
P53 activity is influenced by both the structure of the molecule and its concentration. The 
normal molecule contains three domains which each have a specific function. The N-terminal 
region mainly controls transactivation and the C-terminal region controls oligomerisation, the 
assembly of active tetramers ( 148). Mutations in the C-terminal region may lead to it relocating 
from the nucleus to the cytoplasm. An additional regulatory region controlling the allosteric 
switch from a latent form to an active form, for sequence specific binding is also located in the 
C-terminal (149). The intervening portion of p53 is highly conserved between species and the 
majority of mutations occur in this region. This is the region with DNA binding activity that 
interacts with target sequences of transcriptionally activated genes. Mutations in this region 
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interfere with protein folding and therefore its interaction with DNA. P53 binds in a sequence 
specific manner via its central domain as a tetrameric protein ( 150). 
Interestingly, the study of p53 mutations has shown that specific mutations are more common in 
certain tumours. In high-risk areas of hepatocellular carcinoma (HCC) a well known risk factor 
is aflatoxin. These HCC's are associated with a specific p53 mutation while HCC's in low risk 
areas have more variable mutations ( 151 ). In addition, oesophageal adenocarcinomas and 
squamous cell carcinomas have different patterns of DNA change in the p53 gene. Squamous 
cell carcinoma of the oesophagus, in high risk areas, tends to show a transversion - a change 
from one nucleotide to another (e.g. from a G:C base pair to a T:A base pair) in the p53 core 
domain. While transitions of di nucleotides predominate in oesophageal adenocarcinomas ( 152). 
'Coincidentally' squamous cell carcinomas of the lung tend to show transversions in their 
mutated p53 as well, implicating tobacco as a common carcinogen ( 153). 
Immunohistochemical detection of p53 has been studied intensively and several different anti-
p53 monoclonal antibodies are available. Wild-type p53 is virtually undetectable in normal cells 
because it has a half-life of approximately 20 minutes. Positive immunoreactivity has been 
considered to equate with altered protein structure or function, as a result of mutation or viral 
oncogene activation ( 154 ). However, if antigen retrieval is used (microwave or pressure cooker) 
either wild type and mutant protein can be detected, or at least the threshold for detection is 
lowered ( 155 ). 
P53 in OSCC: 
A number of immunohistochemical studies have consistently demonstrated over expression of 
p53 in OSCC ranging from approximately 40 - 70% in the tumours analysed. There was no 
correlation between p53 over expression and stage, tumour differentiation, lymph node 
metastases, and patient's survival (156-160). Coggi et al (159) also found that p53 aberrations 
do not independently predict prognosis in oesophageal tumours. They also analysed p53 
mutations in exons 5-8, which were detected in 53% of the carcinomas whereas p53 
accumulation was observed in 57% of cases. Comparison of single strand conformational 
polymorphism (SSCP) and immunohistochemical (IHC) analysis revealed 27 discordant cases 
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(38%). Overall, only 27% did not display p53 mutation and/or p53 accumulation. P53 protein
 
accumulation and p53 gene mutation were not related to patient survival by univariate or
 
multivariate analysis in oesophageal carcinomas. 
Coexpression of p53 and vascular endothelial growth factor (VEGF) has been found. This
 
suggests that mutant p53 expression is associated with angiogenesis and distant metastasis in
 
OSCC, and that the coexpression of p53 and VEGF may play an important role in angiogenesis,
 
and have important clinical significance (161 ). A second study looking at these two proteins in
 
OSCC differed in its conclusion finding no significant association between p53 or VEGF 
expressions and prognosis ( 162). 
An interesting study on 153 Chinese oesophagectomy subjects looking at p2 l and p53 
expression showed there was no significant correlation between the expression of p2 l and the
 
abnormal accumulation of p53. The prognosis of patients with absent p2 l expression was better,
 
while the survival rates of patients was worse if they had expression of both p2 l and p53.
 
Consequently, in this study, p21 and p53 had prognostic value for OSCC (163). There are
 
conflicting reports about the value of p53 expression as a prognostic indicator for patients with
 
OSCC. A low level of p53 expression has been correlated with a long term survival (greater than
 
3 years) (164). 
One study revealed that p53 expressing cells in OSCC correlated with the distribution of Ki-67
 
expression and was confined to the basal layer in dysplastic lesion and in the deeper portions of
 
invasive tumours ( 165). 
A step wise over expression of p53 related to normal mucosa, chronic oesophagitis, low grade
 
dysplasia., high grade dysplasia and carcinoma has also been documented ( 166, 167). 
1.8.2 P21: 
The p21 gene is thought to play a central role in tumour suppression. P21WAFl!CIPI (p21) inhibits
 
the activity of the cyclin/cyclin dependant kinase complex and controls the G l to S eel! phase
 
transitkm. The gene product b;nds a,,d inhibits kinase activity of members of the cyclin
 
dependent kinase family thereby preventing progression into the S phase of the cell cycle. It is
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kinase inhibitor blocks cell cycle transition and replication in response to DNA damage. 
Although required for p53-mediated cell cycle arrest, p2 l expression can also be initiated via 
p53-independent pathways. The p21 gene encodes a cyclin-dependent kinase inhibitor which is 
induced by wild-type, but not mutated p53 gene product. P2 l is also associated with cellular 
senescence ( 168) and terminal differentiation ( 169). 
The expression of p2 l in OSCC is reported to range between 14% and 70% via 
immunohistochemical technique, the variability may be related to the clone used ( 163, 170-173). 
An immunohistochemical study of distribution patterns of p2 l and p53 in OSCC and the 
neighbouring non-cancerous squamous epithelia found p2 l protein in the majority of well-
differentiated OSCC, where the p2 l -positive cells were located mainly in the interior/central 
("maturing") layers of the cancer nests. Conversely, p53-positive cells were found mostly in the 
peripheral layers. Cells containing both p21- and p53-positive immunostaining were not 
observed in a double-immunostaining experiment (174). P2 l protein accumulation has been 
reported to show an inverse distribution to that of p53 protein. In areas where both p53 and p2 I 
proteins were accumulated, few apoptotic cells were observed. Particularly in cases of mucosa! 
tumours, p53 protein was prominently accumulated in the lower layer of the tumour, whereas 
p21 protein accumulation was confined to the upper layer (175). Researchers have found 
increased p2 l with irradiation exposure. P2 l production was independent of p53 status ( 176). 
Shirakawa and colleagues in 2000 found that p2 l-expressing cells shifted to the upper layers of 
the epithelium with the progression of dysplasia. They also concluded that p2 l plays a critical 
role in the differentiation process ( 165). Ohashi et al. examined p2 l expression 
immunohistochemically using surgically resected tissues from 25 patients, and analyzed the 
relationship with alteration of p53 gene(l 71 ). All p53-mutation positive cases were negative for 
p2 l expression, whereas 61 % of mutation negative cases showed positive p2 l expression. This 
result implies that p2 l expression is dependant on an intact p53 gene. P2 l expression also 
correlated with tumour grade, well differentiated tumours over expressed p2 l and poorly 
differentiated tumours were negative. The frequency of apoptotic cells was significantly higher 
in p2 l positive cases than negative cases. P21 expressing cells were distributed mainly in the 
middle layers of the invading nests, especially around areas of keratinization, which was similar 
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to the distribution of apoptotic cells. The results of this study suggest that expression of p21 in 
OSCCs is induced by a p53-dependent pathway and affects apoptosis and differentiation of 
carcinoma cells. 
The prognostic significance of p21 was investigated immunohistochemically in samples of 
normal oesophageal squamous epithelium, dysplasia, carcinoma in situ, permanent OSCC cell 
lines, and invasive squamous cell carcinomas treated either by potentially curative resection or 
by combined modality therapy (radiochemotherapy +/- surgery). P21 expression was present in 
the normal epithelium but restricted to a few cells adjacent to the basal cell layer, p21 over 
expression was frequently found in preneoplasias and invasive carcinomas. Expression of p21 in 
invasive carcinomas did not correlate with tumour differentiation or stage. Among carcinomas 
treated by potential curative resection p2 I expression in greater than 50% of cells correlated 
strongly with poor overall survival by univariate (P = 0.0025) and multivariate (P = 0.0081) 
analysis. This group (>50%) also did not respond to combined modality radio/chemotherapy. 
Univariate survival analysis (P = 0.0006) revealed the same prognostic influence in the group of 
patients treated by combined modality therapy. This study therefore concluded that over 
expression of p21 protein is a frequent event in preneoplasia and neoplasia of the oesophagus and 
immunohistochemical examination of p21 expression may provide important prognostic 
information for decision-making in the treatment of patients with oesophageal cancer ( 177). 
Similar conclusions have been reached in other immunohistochemical retrospective studies of 
OSCC who underwent potentially curative resection therapy (111, 163). P21 expression m 
OSCC has also however been shown to be a favourable prognostic indicator ( I 73). 
Loss of p21 expression in OSCC without p53 alternations has been demonstrated indicating that 
other mechanisms are also involved in turning off the gene ( 163). Several studies analysing the 
p21 gene and its association with oesophageal cancer found underlying genetic polymorphism at 
codons 149 and 31 resulted in an increased susceptibility for development of cancer. This 
polymorphism was germline in origin and occurred at a higher frequency in patients with 
premalignant and malignant lesions than in the control population ( 178, 179). The majority of 
the patients with this polymorphism and OSCC expressed wild type p53 ( 180). A study 
performed using normal mucosa, reactive change, low-grade dysplasia, high-grade dysplasia and 
invasive carcinoma specimens and immunohistochemical detection of p21 found a stepwise 
reduction of p2 I (P=O.O 189) with progression to carcinoma ( 181 ). 
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invasive carcinoma specimens and immunohistochemical detection of p21 foun
d a stepwise 
reduction of p21 (P=O.O 189) with progression to carcinoma ( 181 ). 
1.8.3 Cyclin D 1: 
The cyclin D JbcJIIPRAD · 1 gene, located on chromosome 11 q 13, is frequently rear
ranged in 
parathyroid neoplasms and follicular lymphoma. This is currently known to 
be one of the 
earliest proteins expressed at the start/initiation of the cell cycle. It is a proto-oncogene th
at has a 
critical role in G l progression of the cell cycle; it promotes progression of the ce
ll through the 
Gl phase of the cell cycle by cyclin-dependent kinase (CDK) 4 and 6 mediated phosp
horylation 
of the retinoblastoma protein. Its protein product is therefore expressed at high lev
els during the 
G l phase of the cell cycle. The p16 gene and the eye/in DJ gene cooperatively regu
late CDK 4-
mediated phosphorylation of retinoblastoma protein in the cell cycle of normal cel
ls. Cyclin D 1 
functionally competes ·with the tumour suppressor genes retinoblastoma (Rb) and pld
NK4 (182). 
Inhibition of cyclin D 1 therefore arrests the celJ before the S phase, while ov
er expresskm 
contributes to urn;ontrolkd prnliferalion. P21 is invoh·cd in cyclin Dl inhibitio
n. Cyclin Dl 
over expression ranges approximatel)' bet',{ccz, 20 m.d S2~;;. ;;. OSCC { l 8.3, l 84), 
Pul)mcrasc ck,}n reaction to c,aluatc cyclin DJ gene mnplification showed amplifi
cation in 22% 
of primary OSCCs and 25% within the lymph node mctasta5:.:, ~:-,:~p!: ;-;:::d.:: m.::t::,.:
;t:.:::<- t.:,,L:.~ 
t,J be more common in patients \\ ith 91..:lin DJ amplification (70%) than in 
those without 
amplification (37%). Cydin DJ amplification and tner expr.:s.sicm b} imrm.moh1~1,
:<L:=~::_ '0 
1.,~s a:;:',1.x:i~ierl 1.\ ith decreased survival in several studies of OSCC (184-197). 
Cyclin Dl over expression has also been shown to be a significa.,t imfr.:::.1lor of
 !)n,ph m, .. k 
:::.<,:~1;;.::;,::c; OS i-137, ; 96 19.8); ;,11ho11gh rhere arc sporadic studies that have refut
ed this finding 
(199). 
Zheng and colleagues examined the eye/in DJ gene in 21 pairs of primary OSCC an
d the mucosa 
adjacent to the cancers and also in four oesophageal cancer eel! fo:,cs b) mcan.s
 of mokc,,br 
bi,,k~ic:! :md ::-:,m,mnhi ~lo.chcmic<ll techniques. "'\mplification of .. y.:lin DJ gene 
was found in 
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12 out of 21 primary cancers and in oesophageal mucosa adjacent to the tumours
 in five of the 
cases, suggesting this is an early event in the carcinogenesis ( 183 ). 
Shama et al. looked at 36 squamous dysplasias and 34 early OSCC. The frequenc
y of cyclin D 1 
over expression was similar in dysplasias and early cancers (30% vs. 35%). Thi
s study found 
that cyclin D 1 over expression starts early in dysplasia and could be a useful m
arker for its 
malignant potential (200). 
An unusual study linked the Epstein-Barr virus ED-L2 promoter to the human cyc
lin D 1 cDNA 
and utilized this transgene to generate founder lines. This transgene was transcrib
ed specifically 
in the tongue and oesophagus both sharing a stratified squamous epithelium. 
The transgene 
protein product localized to the basal and suprabasal compartments of these squam
ous epithelial 
tissues, and mice from different lines developed dysplasia, a prominent precursor
 to carcinoma, 
by 16 months of age in contrast to age-matched wild-type mice. This transgenic m
odel is useful 
in demonstrating that normal cyclin DI may be a tumour initiating event in aero-u
pper digestive 
squamous epithelial tissues (20 I). 
A subgroup of patients with OSCC get multiple pnmary lesions, about 500/o
 present with 
synchrnnous ksion, whereas the remainder usually present with a second tumour w
ithin the first 
3 years following the initial presentation. Then:fure, a stud) \\as conducted, exa
rnin1ng th~ 
.,;;,.pr.;:..,;ion of 2 pri.:ikin~, ~)din D 1 and p53, in an auempt to predict the occurrence 
of multiple 
. 1· l ('"P' , ... ·. 1 . • ., .,· · .. · ,. "' 1 'D--,. . I , ...
 ·r,,-
pnmary ma 1gnant neop asms .... ·). , .. ,0 .. ~,l, ..... , a.,tn_x,..,,;,;~ k, ..:_...:.""' u, (· l.~-._,;
 ilil,... jL..J {uU-
7) r,r,~;~.;:ins ;-..:re ~sd. Resection sr~drn.::ns from 47 patients, 12 patients with M
P, and 35 
patients with a single primary twnour, "ere anal}zcd. Tho~ in sir,gk primar
: maEsi;~;;,; 
T.;m0.1r ~.,.:r ,:~p;·~::;:;.ion of p53 \.\as also fr"--1..,o;:nt in patients ·;;;.ith MP although s
tatistical 
significance was not achieved. The combination of these two parameters was an
 even greater 
pr.::dictor of ~fP (P<.001 ). Over expression of cydin Dl and pSJ proteins was hig
hly correlated 
with the development of t\.1P (202). 
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Studies on eight OSCC cell lines suggest that the over expressmn of cyclin DI can confe
r 
oesophageal cancer cells with enhanced malignancy through increases in anchorage-independen
t 
growth and VEGF production, and down-regulation of Fas expression, thus suggesting nove
l 
functions of the cyclin D 1 protein in tumour progression (203 ). 
1.8.4 Cyclin E: 
There is a limited amount of information regarding cyclin E and OSCC in the literature. It is 
involved in the cell cycle down stream to cyclin D 1 and its function is activation of cyclin 
dependant kinase 2 (CDK2). Cyclin E's expression is due to phosphorylation of Rb and E2F
 
which first requires cyclin Dl activity. Cyclin E/CDK2 together with cyclin D/CDK4,6 propel
s 
the cell through the initial phase of the cycle into the DNA synthesis phase. Cyclin E has a half
-
life of approximately 20 minutes (204). 
Studies exammmg the relationship between immunohistochemically detected expression o
f 
cyclin E protein in patients with OSCC found a 30% positive rate and could not prove any
 
206). However the study by Ohbu et al using 22 rwrmai '"'''-'--'-""', l 7 rc,H.:fr,,,:; ;,,;b:u,6 ... 22 ;._ ... 
· 
s1~JJ1e, J: .:-ptisi3, } 5 J;iih-graJ.:: J.) splasia and 22 imasive carcinoma specimens revealed a 
stepwise over-expression of Cjdin E \\ ith prugn.::j.,,],_:.,, nf ,_~_:;._,ph,,;ii,,; L~, !:~, c' j~, ~,j2., r,,:,; ;,~,,::,,c 
.. ::.h the i.n.:.rw:.:.eJ .:..:.Ji proliferation observed with Ki67 labelling ( 181 ). 
In conclusion, p53 and p21 proteins inhibit the cdl c:,,...:!.::, v,hik ..:);.;!in E :and ..::;di,, D l pr,,:.:i;:" 
,,:1,.-r p.,rh ,,f :b.: ... :!J ;;;,J ,_,1;1,:r pl,pllbiion groups and to a limited extent the South African
 
OSCC, :dthos1gh ;h~ ,,.:ight of the likniture ,\ould support Cjdin D1 as an independen
t 
prognostic factor. Whether the expression of these cell cycle regulatof) proteins is related to
 
a.etiological risk factors alcohol and tobacco in OSCC merits further investigation. The report
s 




1. To determine the expression of cell cycle regulatory proteins, cyclin E, cyclin 
Dl, p21 and p53, in normal, reactive and malignant oesophageal tissue. 
2. To determine whether the expression, or increasing level of expression, of any, 
or all, of the cell cycle regulatory proteins is related to age at presentation, 
smoking and/or alcohol use and whether expression/over expression of any of 
these proteins predicts survival. 
3. To ascertain whether there is a relationship between the expression of p53 and 
p2 l; and the expression of cyclin DI and cyclin E 
4. To explore prognostic indicators for survival in a sample of patients with 
surgically resected oesophageal squamous cell carcinoma (OSCC). 
5. To determine, by immunohistochemical analysis, whether any human 
papillomavirus (HPV) subtypes, are present in OSCC, normal oesophageal 
mucosa from patients with OSCC or reactive oesophageal lesions. 
2.2 HYPOTHESES 
1. Over expression of cyclin D 1 will be associated with a worse survival. 
2. HPV subtypes will be detected in OSCCs in South African patients. 
3. The stage of the tumour will probably remain the best predictor for survival in 
this sample of 68 patients from Groote Schuur Hospital, South Africa. 
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2.3 PATIENTS AND METHODS: 
Ethics approval for this study was obtained from the Research Ethics Committee, 
University of Cape Town. 
2.3.1 Clinical data 
A central clinical data base was consulted for: age, sex, race, survival or death and a history of 
smoking or alcohol use. Some cases were lost to follow up; survival was then recorded as the 
time between the date of surgery and the date of the patient's last clinical visit (Table 2.1). 
No doubt the survival of some patients was underestimated. 
Table 2.1: The clinical data retrieved from the database for this study. 
Status 
Case Age Sex Race Stage Grade Smoking Alcohol Survival (27.06.03) 
Female Stagel=1 Well=O Smoker=1 Nil=O Deceased=O 
=O Black=O Stagella=2 Moderate Alcohol=1 Alive=1 
Coloured=1 Stage llb=3 =1 non- Unknown Lost to 
Years Male=1 White=2 Stage 111=4 Poor=2 smoker=2 =2 Days follow up=2 
1 54 0 0 2 1 1 1 6001 0 
2 41 1 0 4 1 1 0 2785 0 
3 52 1 2 3 1 1 1 4998 1 
4 57 1 1 2 1 1 1 2575 0 
5 60 1 0 4 1 1 1 8 0 
6 50 1 1 2 2 1 1 4712 1 
7 47 1 0 4 1 1 2 4488 0 
8 31 0 0 2 1 1 0 3892 2 
9 57 1 0 4 0 1 1 477 0 
10 67 1 1 2 0 1 1 737 2 
11 57 1 1 2 0 1 1 262 0 
12 66 1 0 2 1 1 1 182 0 
13 58 1 2 4 2 1 1 620 0 
14 63 1 0 4 0 1 1 116 2 
15 53 1 1 2 0 1 1 39 0 
16 64 1 1 2 1 1 1 74 0 
17 59 1 2 4 1 1 1 47 0 
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Case Age Sex Race Stage Grade Smoking Alcohol Survival Status 
Stagel=1 Well=O Smoker-1 Nil=O Deceased=O 
Female Black=O Stagella=2 Moderate Alcohol=1 Alive=1 
Years 
=O Coloured=1 Stage llb=3 =1 non- Unknown Lost to 
Male=1 White=2 Stage 111=4 Poor=2 smoker-2 =2 Days follow up=2 
18 46 0 1 4 0 1 0 401 0 
19 56 1 0 2 0 1 0 1667 2 
20 63 1 1 2 1 1 1 231 2 
21 41 0 0 2 2 1 1 1993 0 
22 39 1 1 4 1 1 2 26 0 
23 51 1 1 4 1 1 1 42 2 
24 61 1 1 2 1 1 0 3212 0 
25 42 0 0 4 1 0 2 1200 2 
26 48 1 0 4 1 1 2 858 0 
27 57 1 1 3 0 1 1 636 0 
28 37 1 1 2 1 1 1 1180 0 
29 55 1 1 2 1 1 1 45 0 
30 44 1 0 4 2 1 0 652 0 
31 66 1 1 2 1 1 0 19 0 
32 49 1 0 2 1 1 1 16 0 
33 59 1 1 4 0 1 0 131 0 
34 45 1 0 2 1 1 1 201 2 
35 57 1 0 2 1 1 1 1376 0 
36 59 1 1 4 1 1 1 16 0 
37 80 1 1 4 1 1 1 112 0 
38 58 0 1 4 1 0 0 85 0 
39 53 1 1 2 1 1 0 3244 1 
40 51 1 0 4 2 1 1 195 0 
41 45 0 1 4 1 1 1 36 0 
42 50 1 1 4 1 1 1 148 0 
43 74 0 2 4 1 0 1 165 0 
44 52 1 1 1 0 0 0 3119 1 
45 59 1 1 4 1 1 1 372 0 
46 58 1 0 1 1 1 1 39 0 
47 74 0 2 2 2 1 0 2779 1 
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Case Age Sex Race Stage Grade Smoking Alcohol Survival Status 
Stagel=1 Well =O Smoker-1 Nil=O Deceased=O 
Female Black=O Stagella=2 Moderate Alcohol=1 Alive=1 
=O Coloured=1 Stage llb=3 =1 non- Unknown Lost to 
Years Male=1 White=2 Stage 111=4 Poor=2 smoker-2 =2 Days follow up=2 
48 34 0 1 4 1 1 0 598 0 
49 55 1 2 2 1 1 1 55 0 
50 53 0 0 4 1 0 1 302 0 
51 58 1 0 4 2 1 1 318 0 
52 42 0 0 2 0 0 0 2387 1 
53 44 1 0 2 1 1 1 348 0 
54 61 1 1 2 0 0 0 2247 1 
55 50 1 1 2 1 1 1 520 0 
56 52 1 0 2 1 0 1 433 0 
57 58 0 2 1 1 1 1 1715 1 
58 41 0 0 3 1 0 1 175 0 
59 52 1 0 3 0 0 0 429 0 
60 45 1 2 4 2 1 1 126 0 
61 61 0 1 4 1 1 0 92 0 
62 48 0 1 2 1 1 0 1443 0 
63 50 0 1 3 2 1 1 102 0 
64 60 1 0 2 1 1 1 109 0 
65 48 0 1 2 1 0 0 1086 0 
66 23 1 1 3 1 0 0 952 2 
67 53 1 1 2 2 1 1 232 0 
68 30 0 1 2 1 1 0 1012 1 
2.3.2 Pathology 
The histopathology and staging, of all resected squamous cell carcinomas over a 
twenty one year period from 1982 to 2002, were reviewed. Sixty eight patients were 
identified in a data base; they had all had an oesophagectomy for OSCC, at Groote 
Schuur Hospital, a tertiary referral centre. Slides and paraffin blocks were retrieved 
form the archives in the Division of Anatomical Pathology. Haematoxylin and eosin 
(H&E) sections of the tumours were graded according to the WHO (2000) criteria. 
Figure 2.1 illustrates typical examples of well differentiated (Fig.2. lA), moderately 
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differentiated (Fig.2.1B) and poorly differentiated (Fig. 2.lC) OSCCs. A second 
pathologist also performed a randomised review of the slides as a confirmatory 
investigation. 
Figure 2.1: A - a well differentiated tumour, B - a moderately differentiated tumour and C - a 
poorly differentiated OSCC. H&E, x 100. 
In addition, 16 cases of reflux oesophagitis, that showed reactive changes in the squamous 




Two paraffin embedded tissue blocks were then selected from each case, one of tumour and 
one of normal epithelium. Representative blocks of paraffin-embedded tissues were re-cut to 
provide two 4um thick sections of tumour and normal mucosa, and where possible, the 
sections were placed on the same slide. APES-coated slides were used for the 
immunohistochemical studies. For APES-coating slides were washed in Teepol solution, 
thoroughly rinsed in running tap water, rinsed in distilled water and air dried overnight. 
Slides were then 'coated' by immersing them in a 3% solution of APES in acetone for 2 
minutes, rinsing in two changes of acetone with a final rinse in distilled water. The silanised 
slides were dried at 37° overnight. 
The slides were heat fixed on a hot plate at 75° for 30 minutes and allowed to cool to room 
temperature. For de-waxing slides were placed in xylene for three minutes each, with three 
changes. Followed by two changes in 100% alcohol of two minutes each, then followed by 
two changes in 96% alcohol of two minutes each, and followed by one change of two minutes 
in 70% alcohol then rinsed in running water, and rinsed in distilled water. 
Antigen retrieval was done with a pressure cooker. The appropriate buffer (Table 5) was 
brought to boiling point in a pressure cooker without a seal. The slides were generously 
spaced in a metal rack and lowered into the boiling buffer. The pressure cooker was then 
sealed and full pressure maintained for three minutes. The cooker was then removed from the 
heat source and cooled under running water. The lid was then removed and the slides were 
placed in running tap water to avoid drying. Heat-mediated antigen retrinal -..vas performed 
for all five antibodies. 
The five monoclonal antibodies used in this study were anti-p53 (DAKO-done D0-7), anti-
p2l (0!o\ocastra-clone 4Dl0), anti-cyclin Dl (DAKO-clone DCS-6), anti-cyclin E 
(Novocastra-clone J3A3) and anti-HPV (DAKO-ckme K H i8 ). The HP\ am)b._,J.:,. i.:c. k_r;._, •• ,, 
to bind subt)pes 6, i i, i 6, 18, 3 I, 33, 42, 51, 56 and 58, \\hich include the 'high grade' 
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subtypes ( 16, 18, 31 and 33) implicated in cervical carcinoma. The cell cycle regulatory 
protein antibodies are currently thought to be highly specific. 
Endogenous peroxidase was blocked with I% H20 2 in methanol for 20 minutes to prevent 
non-specific staining and slides were rinsed in water. They were then treated with normal 
goat serum (DAKO) for 15 minutes to prevent non-specific binding. Without rinsing they 
were then incubated with individual antibodies at calculated dilutions and for appropriate 
times (Table 2.2). Slides were washed with 0.1 M PBS and 0.05% Tween-20(MERCK). 
Cyclin E, p2 I, p53 and HPV were stained using the Dako Envision system (goat anti-
mouse/peroxidase ), which was applied for 30 minutes. Slides were then rinsed in PBS/Tween 
solution. 
Cyclin D l was stained using LSAB detection system. Biotinylated goat anti-mouse was 
applied as a secondary antibody for 30 minutes, followed by rinsing in PBS/Tween solution. 
This was followed by avidin peroxidase application for 30 mim,tes .:;.,.:! a Iiiij..: ir. PDS.T ;;,..: ...... 
:-- ._,;;'-"' ; .. "' P'"'''"'·'";~.:...:...: ufip;;.:;.:.,i,:m, ·Lq .. iJ DAD i,DAKOf was then applied to all the slides 
for 5 minutes after \\hich tllC) \\ere again ri;,~J 1« PB~. T-.,..:..:«. S.:.::~i.,,,.; -.-• ..:;-..: ~h..:;~ ·, ..... ;:~~..: 
and mounted. 
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Table 2.2: The antibodies used, antigen retrieval, dilutions, incubation times and 
controls. 
Antibody Clone Buffer for Antigen Dilution Incubation Time Controls 
Retrieval with Antibody 
(Figures 2.2.1 -
2.2.5) 
p21 4010 O.OlM Citrate pH6.0 1 :25 120 min Squamous cell 
carcinoma 
p53 00-7 0.01 M Citrate pH6.0 1 :50 60min Squamous cell 
carcinoma 
CyclinDl DCS-6 O.OlM Citrate pH6.0 1 :150 60min Tonsil 
CyclinE 13A3 0.001 M EDT A pH8.0 1:40 120 min Placenta 
HPV KlH8 0.01 M Citrate pH6.0 1:50 60min Cervix(CIN 1) 
Staining was confirmed with known specified positive and negative controis in each 
. . . . . ~ .. . . . ~ . •. . . . , . , .. 
t~~~~..._ ~-"~ :: ... _~ ~~,{,U~;i...t ....... _~ ,l ..... _ ... 1 ... u ... ~u ~~~ ~-...~o1.,U, .c1.J4iJDUU~i. .i)lfh •. nn;; rn.u ~ ... ui-..:r ~n~r~~Jng u~~ UH.;uuauun 
2.4.1 Positive controls for immunohistochemistry: 
Recommended positive controls were used in this study; see Figures 2.2. l - 2.2.5. 
Figure 2.2.1: P21 control. Metastatic squamous cell 
carcinoma to a lymph node revealing distinct nuclear 
staining in malignant squamous cells. X400. 
Figure 2.2.2: Cyclin D 1. Normal tonsillar cells with distinct 
nuclear staining. XlOO. 
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Figure 2.2.3: Cyclin E positive control, normal placenta showing 
crisp nuclear staining oftrophoblastic cells. XlOO. 
Figure 2.2.4: P53 positive control. A squamous cell carcinoma 
of the skin revealing clear nuclear staining in the malignant 
squamous cells particularly the basal cells. XI 00. 
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2.5 STATISTICAL ANALYSIS 
The initial associations were analysed usmg the Spearman rank correlation test. 
Univariate associations between binary categorical variables were analysed using the Chi 
squared test or the Fishers exact test whilst multiple logistic regression was used for 
multivariate analysis. The post-operative period was measured from the date of 
oesophagectomy to the date of death. Patients who were lost to follow-up or confirmed 
alive at the end of the study (23rd June 2003) were considered censored for the purposes 
of survival analysis. Survival ranged from 8 days to 6001 days with a median survival of 
387 days. The Kaplan-Meier method was used to estimate death from oesophageal 
cancer, and the log-rank test was used to estimate statistical significance. Univariate and 
multivariate survival analysis was analysed using the Cox proportional hanrrd modeJ. 
Statistical significance was determined using the 95% confidence interval; P values of 
less than 0.05 were considered statistically significant. AB of the st.afr.:.fa:al i.ii,.;.l3-:;,,.;" n~n..: 
conducted using the STA TA version 7.0 software package. 
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" 
Figure 2.2.5: HPV. Positive control, low grade cervical intra-
epithelial neoplasia showing strong binding to the nuclei of 
infected cells. XlOO. 
Sections of the tissues used as positive controls were also used as negative 
immunohistochemical controls by processing the sections without addition of the primary 
antibody. 
2.4.2 Interpretation of staining: 
Immunostaining was evaluated in coded slides, without knowledge of the tumour stage, 
grade or clinical parameters. In addition, a random audit of the immunohistochemical 
results was carried out by a second pathologist to assess the quality of the stains and for 
confirmation of the results. 
p53, p21 , cyclin E and cyclin DI: As in other studies, nuclear staining in over 
10% of tumour cells was considered a positive result (165, 181, 207-209). One hundred 
consecutive tumour cells where counted in two different representative fields (using 400 
times magnification) and the number of positive cells was then divided by two to get a 
fairly objective percentage. In addition, positive cases were stratified into three groups 





3.1 RESULTS: CLINICAL DATA 
3.1.1 Gender: 
19 (27.9%) of the patients were female and 49 (72. l %) of the patients were male. 
3.1.2 Race: 
26 (38.2%) of the patients were black, 34 (50.0%) were mixed race and 8 (11.8%) were 
white. This distribution possibly reflects surgical selection criteria and the drainage area 
of Groote Schuur Hospital rather than the epidemiology of OSCC. 
3.1.3 Age: 
Age ranged from 23 to 80 years with a mean age of 52. 7 years and a standard deviation 
of l 0.3 years. Thus the mean age at the time of oesophagectomy for this group of 
patients was 52. 7 years (Table 3.1 ). 
Table 3.1: Shows the age distribution for this cohort of patients . 
0 
23 AGE 80 
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3.1.4 Stage: 
Three patients had (4.4%) stage 1 disease, 32 (47.1 %) had stage 2a disease, six (8.8%) 
had stage 2b disease, and 27 (39.7%) had stage 3 disease. For statistical analysis stage 
was stratified into those with no metastatic disease (stage I and Ila) and those with 
metastatic disease (stage Ilb and III) (Table 3.2). 
Table 3.2: Demonstrating survival for those with and without metastatic disease. 
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Kaplan-Meier survival estimates, by ST AGE 
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3.1.5 Grade: 
13 (19.1 %) had well differentiated tumours, 45 (66.2%) had moderately differentiated 
tumours and IO (14. 7%) had poorly differentiated tumours. 
3.1.6 Survival status: 
59 (73.5%) of the patients had died by the end of the study period (January 1982 - 27 
June 2003), 9 (13.2%) were alive at the end of the study period and 9 (13.2%) were lost 
to follow up. 
3.2 RESULTS: CELL CYCLE REGULATORY PROTEINS 
All four markers, p53, p21, cyclin E and cyclin DI, were tested on normal oesophageal 
tissue from the 68 patients. The normal tissue was consistently negative for expression of 
the marker i.e. < I 0% of cell population analysed. Almost all the samples of normal 
mucosa were totally negative (0% of cells positive). 
Sections of tissue in which the diagnosis of OSCC was histologically confirmed showed 
that 42 (61.8%) of the tumours stained positively for p53, 19 (27.9%) stained positively 
for p21, 15 (22%) stained positively for cyclin E and 30 ( 44.1 % ) stained positively for 
cyclin DI (Table 3.3). Figures 3.1 - 3.8 are representative examples of staining, while 
appendix 1 lists the complete results). 
Table 3.3: Levels 1, 2 and 3 of expression of cell cycle regulatory proteins in OSCC 
tissue 
Level of P53 P21 Cyclin E Cyclin Dl 
expression n=68 n=68 n=68 n=68 
0 (0-9%) 26 (38.2%) 49 (72.1%) 53 (77.9%) 38 (55.9%) 
1 (10-25%) 15 (22.0%) 16 (23.5%) 12 (17.7%) 15 (22.0%) 
2 (26-50%) 5 (7.4%) 3 (4.4%) I (1.5%) 11 (16.2%) 
3 (> 50%) 22 (32.4%) 0 (0%) 2 (2.9%) 4 (5.9%) 
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Figure 3.1: P53, level 1 staining (10 -25% of cells positive) staining of OSCC with p53. 
Note the basal pattern of staining, while the more differentiated tumour cells are negative. 
X400. 
Figure 3.2: P53 showing level 3 staining (greater than 50% positive) of OSCC. 
A: Shows some normal epithelium present in the lower left comer with an infiltrating 
OSCC showing strong p53 expression seen in the upper half of the picture. X40. B: 
Shows strong nuclear p53 expression. XlOO. 
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Figure 3.3: P21. A: Shows level I staining (10-25% positive) staining X40. 
B: Shows 
level 2 staining (26 - 50%), with p21 in OSCC. X40. 
Figure 3.4: P2 I , level 2 staining in OSCC. The positive staining is confined to
 the more 
differentiated cells of the squamous nests, while the basal cells tend to be neg
ative. XIOO. 
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Figure 3.5: Cyclin E, staining level I, 2 and 3 {A, B and C respectively) in OSCC. X l 00 
Figure 3.6: Cyclin Dl , staining level 1 and 3 staining, in A and B respectively, m OSCC. 
X40. 
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Figure 3.6: Cyclin D 1, staining level 1 and 3 staining, in A and B respectively, in OSCC. 
X40. 
Figure 3.7: Cyclin DI, level 1, 2 and 3 staining {A, B and C respectively) in OSCC, 
showing the number of positive cells per 100 tumours cells. XlOO. 
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Figure 3.8: Cyclin DI, level 3 staining in the OSCC on the left side, seen undermining 
the overlying benign epithelium on the right which is negative. X25. 
The same antibodies were tested on tissue from 16 inflammatory lesions of the 
oesophagus. In this instance both p53 and cyclin E were I 000/o negative whilst five were 
positive for p21 and two were positive for cyclin DI (Table 3.4 and appendix 2). 
Table 3.4: Levels of expression in reactive oesophageal squamous epithelium 
Level of P53 P21 Cyclin E Cyclin Dl 
expression n=16 n=16 n=16 n=16 
0 (0-9%) 16 (100%) 14(87.5%) 16 (100%) 11 (68.8%) 
1 (10-25%) 0 2(12.5%) 0 5 (31.2%) 
2 (26-50%) 0 0 0 0 
3 (> 50%) 0 0 0 0 
Analysis of the relationship between expression of the proteins in cancerous versus inflamed 
oesophageal mucosa showed a significant difference in the expression of p53. P53 was not 
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expressed in any of the reactive squamous epithelia but was expressed in 61.7% of the tumours 
(p<O.OOO)(Table 3.5). 
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Cyclin E expression in neoplastic compared to reactive tissue approaches significance at 
the 5% level (p=0.063, Fishers exact test). Cyclin DI and p21 's expression was not 
significantly different between malignant and reactive tissue (p=0.409 and p=0.336 
respectively). 
3.3 PROGNOSTIC INDICATORS 
The overall 5 year survival rate of this sample of patients was 30%. The 5 year survival 
in patients without lymph node metastases was 44.9°/o whilst those with nodal metastases 
had a 16.4% 5 year survival. This difference is highly significant (p=0.0074). 
Table 3.6 shows the survival data of the patients included in this study. 
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Table 3.6: Survival graph of the entire group of patients with OSCC plotted in days from 
day O -6000. 
Survival Function 
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Univariate analysis using the Cox proportional hazards model confirmed that those with 
nodal metastases were 2.2 times (95% confidence interval 1.2 to 3.9 times) more likely to 
die from oesophageal cancer post surgery than those without metastases (p=0.009). 
However, univariate analysis of each of the proteins showed that none of them 
independently predicted survival (Table 3. 7). When adjusted for age, gender, stage, 
grade, smoking, alcohol and each other, the proteins remain as non-predictive for 
prognosis in multivariate analysis. 
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Table 3.7: Univariate and multivariate analysis of cell cycle regulatory proteins. 
Variables Univariate analysis of Multivariate analysis 
survival. (full model) 
Hazard Ratio P value Hazard Ratio P value 
P53 l.199 0.533 l.147 0.672 
P21 1.545 0.175 1.862 0.132 
CyclinD1 1.200 0.527 0.899 0.767 
CyclinE 1.391 0.341 1.188 0.653 
Multivariate analysis model building using a forward stepwise approach showed that 
when all the variables were considered (age, sex, stage, grade, smoking, alcohol, p53, 
p21, cyclin E and cyclin DI) only stage and age had prognostic significance (Table 3.8, 
below). The effect of alcohol on survival is not quite significant (p=0.08). 
T ... hk 3.3: Stage and age ;.vhcrc the only two variables of significance in the multivariate 
sun i;. al anal} sis. 
Variables Multivariate analysis 
Hazard Ratio P value Confidence Interval 
Stage 2.439 0.003 1.345-4.421 
Age 1.032 0.030 1.003-1.062 
Thus. when adjusted for age, those with nodal metastases are 2.4 times more likely than 
. . . . . ~ 
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wide, the 95% confidence interval shows that this relationship is significant (CI: 1.0 -
73.7, p=0.049). 
3.4 RESULTS: HUMAN P APILLOMA VIRUS DETECTION 
None of the 68 cases of OSCC, their normal mucosa! counterparts, or any of the 16 
examples of reactive oesophageal mucosa showed any immunohistochemical posifr~ e 




This study investigated 68 patients who underwent oesophagectomy for OSCC. The 
tumours in these patients were assessed for stage, grade, levels of p53, p2 I, cyclin DI, 
cyclin E, as determined by percentage expression, detected immunohistochemically in 
their cancerous and normal oesophageal tissue. The HPV status of each patient's 
oesophagus was also elucidated. For comparison, the same immunohistochemical stains 
were also done on 16 reactive oesophageal lesions from different patients. 
In this study OSCC was more common in males than females (ratio 2.6: 1 ); the racial 
breakdown showed that people of mixed race most commonly underwent 
oesophagectomy at Groote Schuur Hospital, followed by black and then white patients. 
However, the apparent predominance of people of mixed race is due to the geographic 
area drained by the hospital, and the fact that the majority of black patients with OSCC 
come from rural areas and present at advanced stages with tumours that are not amenable 
to surgical intervention. Consequently this study was done on a group of patients 
selected for surgery because the disease was thought to be ·early'; those with clinically 
advanced malignancy are not considered as surgical candidates. Thus, this study is on a 
highly selected group of patients and the findings cannot invariably be extrapolated to all 
cases of OSCC. 
This study group had a 'Guassian' age distribution (mean age = 52.7 years) and age 
proved to be statistically significant with regards to predicting survival (p=0.03, 95% 
confidence interval =1.003-1.06). This meant for every advancing year there was 
statistically a 3% increase in the risk of death. 
In this study, the stage, in particular the presence of nodal or metastatic deposits was 
shown to be the single most significant prognostic factor in survival analysis (p=0.003, 
95% confidence interval = 1.3 - 4.4, hazard ratio 2.439). 
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The 5-year survival rate for the entire group was 30%. Patients without lymph node 
metastases had a 5-year survival of 44.9%, but only 16.4% with nodal metastases 
survived for 5 years. This is in keeping with most large retrospective reports of 
surgically resected OSCC in which the 5 year survival rate is between 29 and 38% (127, 
210-212). Factors such as increased age and advanced stage are associated with a worse 
5 year survival (210). Early stage is consistently associated with a better 5 year survival 
rate as noted in a recently published report from China, where active oesophageal 
screening cytology is taking place. Wang and colleagues (213) report an 86% 5 year 
survival for 420 patients who underwent oesophagectomy for superficial OSCC 
(involving mucosa and submucosa). 
In this study, as in many others (108-112) the grade of the tumour failed to show any 
prognostic significance. A distinctive pattern of staining could however be seen with p53 
and p2 l in the well differentiated, and to some degree, in the moderately differentiated 
OSCCs. P53 was largely confined to the basal layers (Fig. 3.1) while p21 was evident 
just prior to keratinocytic apoptosis, and was particularly evident in the squamous whorls 
(Fig. 3.4). These patterns of expression have been previously reported (174, 175). 
There was no significant relationship between survival and over expression of the various 
cell cycle regulatory proteins; nor between the expression of these proteins and the grade 
and tumour stage. In this study increased p53 expression on its own did not convey any 
prognostic significance as previously reprted ( 156-160). The subgroup of p21 positive 
p53 positive OSCC did not have a worse prognosis compared to the rest of the group as 
previously noted (163). None of the 68 malignancies analysed showed level 3 staining 
for p2 l (>50% of tumour cells showing positive staining) and therefore the previous 
report that this conferred a worse prognosis could not be confirmed ( 177). The finding 
that cyclin DI expression did not convey any significance in predicting survival in this 
study was unexpected. However, other immunohistochemical studies of cyclin D 1 's 
significance as an independent prognostic indicator were conducted on different 
population groups, using differing antibody clones and antigen retrieval methods (186, 
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188. 190, 192). In this context the findings of this study fail to confirm published reports 
of cell cycle regulatory proteins conveying prognostic relevance in OSCC. 
Positive expression of p53 was seen in the OSCCs (61.8%) but not in the normal or 
reactive oesophageal mucosa. Of note was that 22 of the 68 OSCC (32%) expressed p53 
in over 50% of their tumour cells. In addition, p53 was shown to be a significant factor 
in discriminating between reactive lesions and neoplastic lesions (p<0.000). Similar over 
expression of p53 was found in this study in areas of full and partial thickness dysplasia 
(n=3) adjacent to invasive OSCCs. Expression of p53 in dysplastic, preinvasive lesions 
of the oesophagus has been described (214). In addition, stepwise over expression ofp53 
in oesophagitis, dysplasia and neoplasia has also been described in oesophageal 
squamous cell lesions ( 165). These findings suggest that p53 over expression (in > I 0% 
of tumour cells) in formalin fixed, paraffin embedded tissue is specific for neoplasia, but 
unfortunately the sensitivity was only 62%. 
Cyclin E was also over expressed in OSCC (22.1 %), but negative in normal and reactive 
mucosa. The expression of cyclin E was less useful, than p53, in the discrimination 
between reactive and neoplastic lesions but approached significance (p= 0.063). In view 
of the small number of cases showing cyclin E positive staining the statistical 
significance may not be reliable. A larger number of cases may provide more reliable 
results. If the study group was larger cyclin E expression may well have proved 
significant as none of the reactive lesions expressed cyclin E. The positive expression of 
p21 (27.9%) and cyclin DI (44.1%) in OSCC was increased when compared to the 
normal mucosa ( I 00% negative). The expression of p21 and cyclin DI proteins was not 
able to significantly discriminate between reactive and neoplastic lesions. Although the 
reactive group was small none of the reactive lesions showed greater than 25% 
expression (level I) in the mucosa! cells of p21 and cyclin DI. Strong cyclin DI 
expression (>26% of cells/level 2) was seen in 22.1 % of OSCC. Thus, level 2 or greater 
expression of cyclin DI could be useful in distinguishing between reactive and neoplastic 
lesions. 
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More importantly, cyclin DI was noted to be significantly over expressed in those 
patients who smoked compared to non-smokers. This finding may well warrant further 
investigation in OSCC and other smoking related lesions. Over expression of cyclin DI 
has been documented in oral cavity dysplasia/malignancy and in squamous lesions in the 
bronchus (metaplasia, dysplasia and neoplasia) (209, 215). Cyclin DI expression is 
clearly related to smoking. Importantly, future studies of eye! in DI and survival should 
consider whether smoking is a confounding factor when assessing the independent 
prognostic significance of cyclin DI. Cyclin DI over expression is currently considered 
an early event in the carcinogenesis of OSCC ( 199) and its expression may well be 
related to chronic irritation which results in increased cell turnover. 
No relationship could be demonstrated between the presence or absence of expression of 
the various cell cycle proteins in the neoplastic tissue. In particular, p53 and p2 l did not 
demonstrate inverse or related expression. Neither could a relationship between cyclin 
D 1 and cyclin E expression be found. 
The initial aim of this study was to investigate the role of HPV, using 
immunohistochemical staining, in OSCC but the negative results necessitated a shift in 
the focus of this study to that of cell cycle regulatory proteins. The absence of 
immunohistochemically detectable HPV in this study was an unexpected result. 
Particularly, since this finding was discordant with that of fellow investigators who 
examined tumour tissue from many of the same patients. using PCR techniques, and 
found an approximate 20% prevalence of HPV in their sample (unpublished data, 
personal communication with Professor I Parker, Department of Medical Biochemistry, 
University of Cape Town). 
This adds to the observation that the different method used to detect HPV result in 
differing prevalence rates. The clone used in this study (K 1 H8-Dako) was a monoclonal 
mouse anti-HPV antibody delivered in a fetal calf serum tissue culture supernatant. The 
antibody reacts with the non-conformational internal linear epitope of a major capsid 
protein (VP I) that is broadly expressed amongst the different HPV subtypes. It has been 
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shown to identify HPV l in ELISA and to detect HPV 1 and 6 by indirect 
immunoflourescence in infected frozen tissues. In addition, the antibody has been shown 
to be immunoreactive with paraffin sections of formalin fixed tissue demonstrated by 
Southern blot hybridisation to be infected with HPV types 6, 11, 16, 18, 31, 33, 42, 51, 
52, 56 and 58 (216). Hence, if full viral particles of these types are formed with an intact 
capsid they should be detectable by immunohistochemical methods. However, if the 
virus has been integrated into the cellular genome/deoxyribonucleic acid (DNA) and is 
not replicating it would be unlikely that this particular antibody would detect it. PCR 
would most likely identify any viral DNA sequences present. The vast majority of PCR 
studies from areas of high incidence have found a high prevalence of HPV DNA in 
OSCC. Other immunohistochemical studies, that have identified HPV in OSCC used 
different clones ( 3 7, 3 8 ), while another study demonstrating positive staining used a 
different anti-HPV capsid clone (53). 
There is now sufficient 'literature' to support the hypothesis that HPV does infect the 
oesophageal mucosa and becomes integrated into the genome of some patients; recent 
publications report that high grade cervical dysplasia is associated with, and requires the 
integration ofHPV into the genome (217,218). Once integrated into the genome, HPV is 
capable of modulating the p53 and retinoblastoma gene products and contributing to 
carcinogenesis. Therefore, the absence of immunohistochemically detectable HPV 
capsid antigen in the 68 patients studied would imply that there was no active viral 
replication. This does not exclude the possibility that HPV is incorporated into the 
genome and may play an important role in aetiopathogenesis of OSCC. The patients 
included in this study were from an urban and peri-urban environment predominantly and 
not the high incidence areas of the Eastern Cape. 
While the cell cycle regulatory proteins were not predictive of survival they have been 
shown in several studies to be useful in predicting a response to therapy. Studies of the 
predictive value of p53, to determine whether the effectiveness of radiotherapy could be 
predicted, showed over expression of p53 was been associated with an unfavourable 
treatment response and negative p53 expression with a favourable response (219-221 ). 
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The efficacy of combined chemo-radiotherapy in relation to p53 expression, found a h
igh 
level of p53 expression in operated specimens was associated with unfavorable tum
our 
response to preoperative treatment. Therefore, immunohistochemical detection of 
p53 
protein was predictive of the outcome of preoperative therapy (222). 
Potential therapeutic interventions have been studied analysing adenoviral-medi
ated 
wild-type p53 gene therapy on oesophageal cancer cell lines with promising results.
 A 
significant growth suppression following an Ad5CMV-p53 infection was observed
 in 
both cancer cell lines. A Western blot analysis confirmed the presence of both exogen
ous 
p53 protein expression and p2I protein induction. Apoptotic cell death was obser
ved 
with TUNEL staining (223 ). 
P21 and p53 have been studied in patients who received preoperative chemotherapy
 for 
OSCC and subsequently underwent oesophagectomy with lymph node dissection. 
The 
positive rate ofp53 and p21 expression was 56.7% and 36.7%, respectively. Preopera
tive 
chemotherapy was ineffective in all the patients who expressed p53, but not p21. 
In 
contrast, chemotherapy was effective in patients with lymph nodes metastases that w
ere 
p53 negative but p2 l positive. These findings suggest that p2 l positive expression, in
 the 
absence of p53, is associated with favorable effects of preoperative chemotherapy
 in 
patients with OSCC (224 ). 
One study looked at a recombinant adenoviral approach and gene gun technology
 to 
introduce p2 l into oesophageal cancer cells in order to assess the effect of p2 l on c
ell 
growth. Infection with the p2I adenovirus (AdV) resulted in inhibition of malign
ant 
oesophageal squamous cell lines. The levels of involucrin, which is a marker
 of 
squamous epithelium differentiation, markedly increased at 48 h and 72 h after p2 l A
dV 
infection. These results indicate that p2I plays an important role in oesophageal can
cer 
cell proliferation. Over expression of the p2 l gene can inhibit cell growth and ind
uce 
differentiation in oesophageal cancer cells. P2 l gene therapy may prove beneficial in
 the 
treatment of oesophageal cancer (225). 
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Cyclin 01 expression may also be important regarding patients receiving chemo-
radiotherapy. Among 34 patients with OSCC, differences in the responsiveness to 
chemoradiotherapy were correlated with cyclin D 1 immunoreactivity assessed in the 
biopsy specimens. This study found that the cyclin D 1 negative group responded 
favourably compared to the positive group. Thus the cyclin 01 protein may be a useful 
predictor of sensitivity to concurrent chemo-radiotherapy for OSCC (226). 
4.2 CONCLUSION: 
In conclusion, this study confirmed that expression of the cell cycle regulatory proteins 
cyclin D 1, cyclin E, p21 and p53 did not convey any prognostic significance in a group of 
patients who underwent oesophagectomy for OSCC. Nor is expression of these proteins 
related one to another, or to stage, age, grade and alcohol use. 
Cyclin DI was found to be over expressed in smokers versus non-smokers. 
P53 is specific, but not sensitive, for discriminating between reactive and neoplastic 
oesophageal lesions. The expression of cyclin E may also be useful in this regard. 
Differences between this study and previous reports of cell cycle regulators conveying 
independent prognostic significance may be related to the population studied, antigen 
retrieval methods, different antibody clones, methodology used for antibody binding and 
in some cases differing methods of statistical analysis. 
HPV could not be demonstrated, using immunohistochemical techniques, in this group of 
patients with OSCC. 
Younger patients had a better survival than older patients, with increasing age 
significantly increasing the risk of mortality. Lastly, histopathological staging, in 
particular the presence of nodal or other metastatic disease, remains the most important 
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prognostic indicator in these patients. Any clinical intervention enabling early detection 
of OSCC should be wholeheartedly endorsed. 
4.3 RECOMMENDATIONS: 
I. Exploration of the relationship between cyclin DI and smoking; this might shed 
light on understanding the molecular pathology of smoking related neoplastic 
lesions. 
2. Prospective studies to confirm whether expression of p53, p2 l and cyclin DI 
determines a response group to chemo- and/or radiotherapy. 
3. The various methods used to detect HPV should be compared using the same tissue 
samples taken from high incidence areas of OSCC and the biological reason for 
varying detection explored. 
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APPENDIX: 
1. IMMUNOHISTOCHEMICAL RES UL TS FOR OSCC: 
Where, n = normal tissue and t = tumour. 
~ase p53n p53t p21n p21t cyclinEn cyclinEt cyclin01n cyclin01t 
1 0 0 0 0 0 0 0 0 
2 0 0 0 1 0 1 0 2 
3 0 1 0 0 0 0 0 2 
4 0 0 0 1 0 0 0 3 
5 0 2 0 0 0 0 0 1 
6 0 3 0 0 0 0 0 0 
7 0 0 0 0 0 0 0 1 
8 0 0 0 0 0 0 0 2 
9 0 3 0 0 0 0 0 C 
10 0 3 0 0 0 0 0 1 
11 0 3 0 1 0 0 0 1 
12 0 0 0 0 0 0 0 1 
13 0 1 0 0 0 0 0 0 
14 0 2 0 1 0 0 0 1 
15 0 1 0 0 0 0 0 0 
16 0 0 0 0 0 0 0 3 
17 0 0 0 1 0 1 0 1 
18 0 3 0 0 0 1 0 2 
19 0 0 0 0 0 0 0 0 
20 0 3 0 1 0 1 0 0 
21 0 1 0 0 0 1 0 0 
22 0 1 0 1 0 0 0 C 
23 0 1 0 2 0 1 0 1 
24 0 0 0 0 0 0 0 0 
25 0 3 0 0 0 1 0 0 
26 0 0 0 0 0 0 0 0 
27 0 0 0 0 0 0 0 0 
28 0 1 0 0 0 0 0 0 
29 0 0 0 0 0 0 0 0 
77 
Case p53n p53t p21n p21t cyclinEn cyclinEt cyclinD1n cyclinD1t 
30 0 0 0 0 0 0 0 0 
31 0 3 0 0 0 1 0 C 
32 0 0 0 1 0 0 0 1 
33 0 0 0 0 0 0 0 0 
34 0 3 0 0 0 0 0 0 
35 0 0 0 0 0 0 0 0 
36 0 3 0 1 0 0 0 0 
37 0 3 0 0 0 1 0 0 
38 0 3 0 0 0 0 0 0 
39 0 3 0 0 0 0 0 2 
40 0 3 0 0 0 0 0 0 
41 0 2 0 0 0 0 0 2 
42 0 1 0 0 0 0 0 2 
43 0 3 0 0 0 0 0 0 
44 0 0 0 0 0 0 0 0 
45 0 0 0 0 0 0 0 3 
46 0 1 0 0 0 0 0 2 
47 0 2 0 1 0 0 0 1 
48 0 0 0 1 0 0 0 1 
49 0 3 0 1 0 0 0 3 
50 0 1 0 0 0 0 0 0 
51 0 1 0 0 0 2 0 0 
52 0 3 0 0 0 0 0 0 
53 0 3 0 0 0 0 0 1 
54 0 3 0 0 0 0 0 0 
55 0 0 0 0 0 0 0 2 
56 0 1 0 0 0 3 0 0 
57 0 1 0 0 0 0 0 0 
58 0 0 0 1 0 1 0 1 
59 0 3 0 0 0 0 0 0 
60 0 0 0 0 0 0 0 0 
61 0 1 0 1 0 0 0 2 
62 0 0 0 1 0 0 0 2 
63 0 3 0 0 0 1 0 0 
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Case p53n p53t p21n p21t cyclinEn cyclinEt cyclinD1n cyclinD1t 
64 0 1 0 2 0 3 0 0 
65 0 0 0 0 0 0 0 1 
66 0 0 0 2 0 0 0 0 
67 0 3 0 1 0 0 0 1 
68 0 2 0 0 0 1 0 a 
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2. IMMUNOHISTOCHEMICAL RESULTS FOR REACTIVE 
OESOPHAGEAL TISSUE. 
case Cyclin 01 Cyclin E P21 P53 
1 0 0 0 0 
2 0 0 0 0 
3 0 0 0 0 
4 1 0 0 0 
5 0 0 0 0 
6 0 0 1 0 
7 1 0 0 0 
8 0 0 0 0 
9 1 0 0 0 
10 1 0 1 0 
11 0 0 0 0 
12 1 0 0 0 
13 0 0 0 0 
14 0 0 0 0 
15 0 0 0 0 
16 0 0 0 0 
total 5 0 2 0 
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